PT-141 (Bremelanotide) — MC4R-Selective Melanocortin Agonist

Discovery and development

PT-141, now known by its international nonproprietary name bremelanotide, was developed by Palatin Technologies in the early 2000s as a selective derivative of Melanotan II (MTII), a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). The origin of the melanocortin peptide lineage traces to research on tanning peptides in the 1980s, during which investigators noticed unexpected sexual side-effects in subjects and animals administered MTII [PMID:11313765]. MTII's pan-melanocortin activity — spanning MC1R through MC5R — produced both its tanning effects via MC1R and its central arousal effects via MC4R, but also created tolerability limitations including nausea and, with cumulative dosing, skin hyperpigmentation.

Palatin Technologies pursued a structural optimisation programme aimed at retaining MC4R agonist activity while minimising MC1R engagement. The result was bremelanotide: a cyclic heptapeptide with N-terminal acetylation and a lactam bridge between the aspartic acid and lysine residues that constrains the backbone into a bioactive conformation favourable to MC4R binding [PMID:14660174]. The substitution of norleucine (Nle) for methionine at the N-terminus and the incorporation of D-phenylalanine at position three further rigidified the structure and improved metabolic stability relative to linear melanocortin analogues.

This selectivity engineering addressed a fundamental liability of MTII: by reducing affinity at MC1R, the pigmentation risk associated with chronic dosing was substantially attenuated, though not entirely eliminated at high cumulative exposures. Palatin subsequently progressed bremelanotide through Phase I, Phase II, and finally Phase III evaluation — culminating in FDA approval in June 2019 under the brand name Vyleesi for premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD).

Mechanism of action

PT-141 exerts its primary pharmacological effects through selective agonism at the melanocortin 4 receptor (MC4R), a G-protein coupled receptor predominantly expressed in hypothalamic nuclei and limbic structures including the medial preoptic area, paraventricular nucleus, and nucleus accumbens shell [PMID:14660174]. This central receptor distribution distinguishes PT-141 mechanistically from phosphodiesterase-5 (PDE5) inhibitors such as sildenafil, which act peripherally on vascular smooth muscle; PT-141 acts upstream in the neural circuitry governing desire rather than downstream on the haemodynamic response.

MC4R activation and dopaminergic neuromodulation. MC4R coupling to Gs proteins increases intracellular cyclic AMP (cAMP) in hypothalamic neurones, ultimately facilitating dopamine release within the mesolimbic pathway [PMID:11313765]. Elevated mesolimbic dopamine tone is associated with appetitive motivation — the wanting component of sexual desire — which is the primary pharmacological endpoint targeted by PT-141. Animal models using MC4R knockout mice demonstrate complete abolition of the peptide's pro-sexual effects, confirming MC4R as the obligate effector receptor [PMID:14660174].

Melanocortin-oxytocin interaction. Hypothalamic MC4R neurones project to oxytocinergic populations in the paraventricular nucleus. PT-141 administration in rodent models augments oxytocin release, which contributes to affiliative and consummatory sexual behaviour as a downstream neuromodulatory event [PMID:11313765]. This MC4R-to-oxytocin axis is thought to contribute to the desire-and-anticipation quality of the peptide's effect, as distinct from the peripheral vasodilation component.

Peripheral vasodilation. Beyond central effects, MC4R receptors are present on vascular endothelium and smooth muscle. PT-141 administration produces transient increases in genital blood flow in both sexes — in women via increased vaginal lubrication and engorgement; in men via penile tumescence — through nitric oxide-mediated vasodilation [PMID:16409223]. This peripheral component is additive to, rather than the primary mechanism of, the compound's desirogenic profile.

MC1R engagement and pigmentation. Although PT-141 has substantially lower MC1R affinity than MTII, some residual MC1R agonist activity is present at higher cumulative doses. MC1R activation in dermal melanocytes upregulates melanin synthesis, and with repeated dosing this can manifest as hyperpigmentation (discussed further in the safety section).

Researched applications

Hypoactive sexual desire disorder — Phase III RECONNECT trial. The pivotal evidence base for PT-141 is the RECONNECT programme, a pair of multicentre, randomised, double-blind, placebo-controlled Phase III trials enrolling premenopausal women with acquired, generalised HSDD [PMID:31599840]. Participants self-administered subcutaneous bremelanotide (approximately 1.75 mg) or placebo as needed, at least 45 minutes before anticipated sexual activity, for 24 weeks. The co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. Both trials met their primary endpoints; bremelanotide produced statistically significant improvements in desire scores and reductions in sexual distress relative to placebo. These results supported the June 2019 New Drug Application approval.

Erectile dysfunction — Phase II evaluation. Diamond et al. conducted a Phase II randomised crossover study evaluating subcutaneous bremelanotide in men with erectile dysfunction that was at least partially refractory to sildenafil, including a cohort with documented psychogenic ED [PMID:16409223]. Bremelanotide produced significantly higher erectile function scores and a greater proportion of sexual encounters with successful vaginal penetration compared with placebo. Critically, the effect was observed across both vascular and psychogenic ED subgroups, consistent with the central mechanism providing benefit independent of PDE5 pathway integrity. Phase III development in erectile dysfunction was not pursued by Palatin, but this Phase II dataset remains frequently referenced in research contexts.

Animal models of sexual behaviour. Pfaus and colleagues characterised bremelanotide's pro-sexual effects extensively in rat models prior to human trials, demonstrating increased solicitation behaviour and lordosis quotient in females and shortened mount latency in males at doses that did not produce overt sedation or aversive responses [PMID:11313765]. These translational findings informed the dosing strategy carried into human trials.

Dosing range

In the FDA-approved Vyleesi formulation, the commercial dose is 1.75 mg administered subcutaneously via a single-use autoinjector into the abdomen or thigh, taken approximately 45 minutes before anticipated sexual activity. Dosing should not exceed one administration per 24-hour period and the prescribing information recommends a maximum of eight doses per month [PMID:31599840].

In Phase II research settings evaluating erectile dysfunction and other outcomes, dose-ranging work explored subcutaneous doses of 1 mg and 2 mg, with the 2 mg dose demonstrating comparable efficacy but a higher frequency of nausea and transient blood pressure elevation [PMID:16409223]. Doses above 2 mg SC have not been studied in controlled human trials and are not represented in the published safety database.

The historical intranasal route — used in some early Phase I and Phase II studies — has been discontinued in favour of subcutaneous administration. Intranasal delivery produced inconsistent systemic absorption and a higher rate of upper respiratory adverse effects; the pharmacokinetic profile was considered inferior to SC injection for reliable dosing.

For research purposes outside the approved indication, the literature supports a working range of approximately 1 mg to 2 mg SC per administration, with a minimum inter-dose interval of 24 hours to limit cumulative cardiovascular and pigmentation exposure. Research protocols typically specify an administration window of 30 to 90 minutes prior to the observation period, consistent with the peptide's plasma half-life of approximately two hours.

Safety profile

The safety database for PT-141 is more extensive than for most research peptides, given that Vyleesi has completed Phase III trials and undergone FDA post-marketing surveillance.

Flushing. The most frequently reported adverse effect in clinical trials is facial flushing, which occurs in approximately 40% of participants across the RECONNECT trials at the approved 1.75 mg dose [PMID:31599840]. Flushing is typically mild-to-moderate, transient (resolving within one to two hours), and attributable to peripheral vasodilation mediated through melanocortin receptors on cutaneous vasculature.

Nausea. Nausea was reported in approximately 40% of participants and was the leading cause of study discontinuation. It typically begins within the first hour post-injection and resolves spontaneously within two to four hours. Administration of an antiemetic prior to dosing is not part of the approved protocol but has been used in research settings to improve tolerability.

Transient hypertension. Blood pressure monitoring in Phase II and Phase III studies identified mean increases of approximately 6 mmHg systolic and 3 mmHg diastolic peaking at approximately one hour post-dose, with return to baseline within twelve hours [PMID:16409223]. The FDA label carries a contraindication for patients with known cardiovascular or cerebrovascular disease and a precaution regarding concomitant antihypertensive use, as haemodynamic additive effects cannot be excluded.

Hyperpigmentation. With repeat dosing, residual MC1R agonist activity can accumulate sufficient stimulation of dermal melanocytes to produce localised or generalised hyperpigmentation — most frequently observed on the face, breasts, and genitalia in Phase III participants who received the highest cumulative bremelanotide exposure [PMID:31599840]. This effect is dose-cumulative and dose-frequency-dependent; it was not fully reversible in all cases within the study follow-up window, which reinforces the prescribing information's warning to limit monthly dose frequency.

Contraindications and interactions. Bremelanotide is contraindicated alongside any drug that significantly affects cardiovascular haemodynamics or sensitises the QT interval without adequate monitoring. It should not be used concomitantly with indomethacin, as pharmacokinetic interaction studies demonstrated reduced bremelanotide exposure when co-administered, likely due to altered renal elimination [PMID:31599840].

UK regulatory status 2026

Bremelanotide does not hold a Marketing Authorisation granted by the Medicines and Healthcare products Regulatory Agency (MHRA). Vyleesi is not licensed in the United Kingdom and has not received an equivalent approval from the European Medicines Agency (EMA). The compound therefore cannot be lawfully prescribed, sold, or supplied for human therapeutic use within the United Kingdom under the Human Medicines Regulations 2012.

Researchers operating in accredited in vitro laboratory environments may handle bremelanotide as a research chemical for cell-based or receptor-binding assays without a Medicinal Product licence, provided no human or animal administration is involved. Any in vivo animal work requires appropriate Home Office project licences under the Animals (Scientific Procedures) Act 1986.

Importation of PT-141 for personal human use is not authorised by MHRA licensing and may be subject to seizure at the UK border. Individuals residing in jurisdictions where bremelanotide is approved — including the United States — may access Vyleesi through licensed prescribers and authorised pharmacies within that jurisdiction.

Reconstitution and storage

Research-grade PT-141 is supplied as a lyophilised white powder, typically in vials of 2 mg or 5 mg. Reconstitution should be performed using bacteriostatic water (0.9% benzyl alcohol) added dropwise along the inner wall of the vial to minimise foaming. Swirl gently for 30 to 60 seconds; do not vortex or shake. A standard working concentration of 1 mg/mL or 2 mg/mL is typically prepared to allow accurate volumetric dosing with insulin syringes.

Reconstituted peptide stored at 2 to 8°C in a sealed, amber or light-protected vial retains reported stability for approximately 28 days. Lyophilised powder should be kept desiccated at or below 25°C, away from direct light and moisture; under these conditions the manufacturer-stated shelf life is typically 24 months. Single-use aliquots of reconstituted solution may be stored at -20°C and thawed once immediately prior to use; repeated freeze-thaw cycles promote aggregation and should be avoided.

Frequently asked research questions

How does PT-141 differ mechanistically from PDE5 inhibitors? PDE5 inhibitors (sildenafil, tadalafil) act peripherally on vascular smooth muscle by preventing cGMP breakdown, thereby augmenting vasodilation in genital tissue only after sexual stimulation has already initiated the NO-cGMP cascade. PT-141 acts centrally at hypothalamic MC4R receptors to augment the appetitive desire component of sexual function — the neurally generated drive to seek sexual activity — independently of whether peripheral stimulation has occurred. The two mechanisms are complementary rather than redundant.

Is PT-141 effective in postmenopausal women? The FDA approval specifically covers premenopausal women with acquired generalised HSDD. The RECONNECT trials did not enrol postmenopausal participants; the hormonal milieu differences (particularly reduced oestrogen, which modulates MC4R expression in limbic tissue) make extrapolation uncertain. Off-label research use in postmenopausal subjects has been reported anecdotally but is not supported by controlled trial data.

Can PT-141 be combined with PDE5 inhibitors? No formal drug-drug interaction study with PDE5 inhibitors has been published in the peer-reviewed literature. The combination is pharmacologically plausible — central desire augmentation paired with peripheral vasodilatory support — but additive cardiovascular effects (hypotension, tachycardia) have not been characterised in a controlled setting.

Does PT-141 affect hormone levels? Published pharmacokinetic and pharmacodynamic studies have not detected consistent changes in circulating sex hormones (testosterone, oestradiol, LH, FSH, or prolactin) following single or repeated subcutaneous doses in the 1 to 2 mg range. The mechanism is neuromodulatory rather than endocrinological, which is consistent with the central cAMP/dopamine signalling pathway through which MC4R operates.

Does tanning occur with standard single doses? Transient mild flushing of the skin is common (and is vasodilatory rather than melanogenic), but true melanin-mediated hyperpigmentation requiring sustained MC1R stimulation was observed in Phase III only after multiple cumulative doses — not with a single administration. Researchers monitoring for this effect should document any progressive localised darkening with repeat exposures.

---

PT-141 appears in the following research stacks on this site: PT-141 + Kisspeptin Libido Stack, Melanotan II + Bremelanotide Tanning Stack.

Source research-grade PT-141

PT-141 (Bremelanotide) — MC4R-Selective Melanocortin Agonist is sold for laboratory and in vitro research use only. UK regulatory status: FDA-approved as Vyleesi (2019) for premenopausal HSDD. Not licensed in UK by MHRA — research use only outside US..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk